Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (the "Company") on July 18, 2025. The filing reports the entry into a Third Amendment to the Agreement and Plan of Merger with Decoy Therapeutics Inc. ("Decoy"). The Company is a Delaware corporation listed on the Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics and Transaction Structure
The filing details a capital restructuring within the context of a pending merger rather than standard operating financial results.
- Ownership Structure: Following the merger, legacy Salarius stockholders will retain 7.6% and legacy Decoy stockholders will retain 92.4% of the combined company (pre-qualified financing).
- Qualified Financing: The transaction is contingent on a minimum $6.0 million qualified financing.
- Debt-to-Equity Exchange: Certain holders of Decoy's non-convertible promissory notes will exchange debt for newly created Series B Non-Voting Convertible Preferred Stock.
- Conversion Ratio: The Series B Preferred Stock has a conversion ratio of 1,000 shares of common stock per preferred share.
Material Changes Versus Prior Period
The primary material change is the amendment of the Merger Agreement to facilitate the exchange of Decoy Promissory Notes for Series B Preferred Stock.
- Ownership Dilution Adjustment: The number of common shares underlying the Series A Preferred Stock (issued to existing Decoy stockholders) will be reduced on a one-for-one basis by the shares issued for the Series B Preferred Stock. This ensures the relative percentage ownerships of the combined company remain unchanged from previously disclosed figures.
- Redemption Obligations: The Company is now obligated to use 50% of net proceeds from post-closing drawdowns under its At-the-Market Program or equity line of credit to redeem outstanding Series B Preferred Stock until fully redeemed.
Guidance, Outlook, and Risks
Management Commentary and Mechanics:
- Closing Timing: The Note Exchange Agreements must close immediately following the closing of the Merger.
- Conversion Triggers: Series B Preferred Stock may convert upon stockholder approval and satisfaction of Nasdaq initial listing standards. Mandatory automatic conversion occurs one year after the Conversion Approval Date.
- Redemption Price: Defined as the lower of (i) the S-1 offering price multiplied by 1,000, or (ii) 1,000 times the weighted average effective per share offering price of any subsequent offering of at least $2.0 million.
Risks and Contingencies:
- Listing Requirements: Conversion is subject to Nasdaq listing rule 5635 and the Company's satisfaction of initial listing standards.
- Financing Dependency: The transaction structure relies on the successful completion of the $6.0 million Qualified Financing.
Financial Data: The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt levels outside of the specific note exchange context.
Investor Verification Checklist
- Verify the status of the $6.0 million Qualified Financing required to close the merger.
- Confirm the exact principal and interest amounts of the Decoy Promissory Notes being exchanged for Series B Preferred Stock.
- Review the At-the-Market Program terms with Ladenburg Thalmann & Co. Inc. and the equity line of credit with C/M Capital Master Fund, LP to assess the redemption cash flow impact.
- Monitor progress toward Nasdaq initial listing standards and stockholder approval for the conversion of preferred stock.
- Examine the full text of the Third Amendment (Exhibit 2.1) and Certificate of Designation (Exhibit 2.2) for detailed legal terms.